Systems and methods for testing and screening using compound bound substrates
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12282015-B2
Publication Date
2025-04-22
Expiration Date
Abstract
The present disclosure provides compositions, methods, kits and systems for detecting antibodies in a biological sample. In some embodiments, methods/systems are particularly useful for detecting antibodies in patients against pathogen-inactivating compound treated RBCs.
Core Innovation
A method is provided for administering a red blood cell transfusion using red blood cells treated with a pathogen-inactivating compound identified as β-alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester (S-303-treated RBCs). The method includes testing a patient serum or plasma sample for the presence of antibodies reactive to the S-303-treated RBCs.
The antibody testing includes contacting the sample with a first substrate having a moiety bound to the surface, where the surface-bound moiety results from treating the first substrate with a compound of Formula VIII. An amount of binding between antibodies from the sample and the surface-bound moiety is assayed as compared to a reference using a second substrate that is the same as the first substrate but lacks the surface-bound moiety.
The method determines whether the amount of binding is higher than the reference, and administers the red blood cell transfusion in accordance with the determination that the amount of binding is not higher than the reference. The substrates include polymeric particles, matrices, assay plate portions, and red blood cells, and the surface-bound moiety is defined by Formula VIII and related formula classes.
Claims Coverage
The provided material identifies one independent claim. It covers a patient-specific antibody reactivity test for S-303-treated RBCs using a substrate-based surface-bound moiety derived from Formula VIII and a matched reference substrate lacking the moiety, with transfusion administration when binding is not higher than the reference. Overall, the independent claim includes three inventive features.
Conditioning transfusion administration on antibody binding relative to a reference lacking the moiety
A method of administering a red blood cell transfusion comprising S-303-treated RBCs, comprising testing a patient serum or plasma sample for presence of antibodies reactive to the S-303-treated RBCs by assaying an amount of binding between antibodies and a surface-bound moiety of a first substrate as compared to a reference second substrate that lacks the surface-bound moiety, determining whether the amount of binding is higher than the reference, and administering the transfusion in accordance with the determination that the amount of binding is not higher than the reference.
Using a first substrate bearing a surface-bound moiety derived from Formula VIII
The method includes contacting the serum or plasma sample with a first substrate wherein a moiety is bound to the surface of the first substrate, and wherein the surface-bound moiety resulted from treating the first substrate with a compound of Formula VIII.
Employing a matched reference substrate lacking the surface-bound moiety
The method assays an amount of binding between antibodies from the sample and the surface-bound moiety of the first substrate compared to a reference, wherein the reference is a second substrate that lacks the surface-bound moiety and is the same as the first substrate.
The independent claim covers an S-303-treated RBC transfusion administration method that relies on a comparative antibody-binding assay. The assay uses a moiety-bearing substrate formed from a Formula VIII compound, a matched reference substrate lacking the moiety, and determines transfusion administration based on whether the measured binding amount is higher than the reference.
Stated Advantages
Enables administering the red blood cell transfusion in accordance with a determination based on antibody reactivity to S-303-treated RBCs indicated by binding relative to a reference substrate lacking the surface-bound moiety.
Documented Applications
No documented applications found
Interested in licensing this patent?